Security
Bioadaptives, Inc. Common · BDPT
BDPTOTCCommon stockHistorical · closed Aug 24, 2015CIK 1575142Updated Oct 7, 2026
Name history
APEX 8 Inc. · through Aug 19, 2013
Current security for this SEC filerBDPT · OTC
BDPT price & chart
Historical security
This listing closed Aug 24, 2015. Live provider charts are shown only for current listings.
Current security: BDPT
About the company
BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.
In the news
BioAdaptives introduces MyndSystem™, an integrated Neuro-Performance & Repair system for day and night ↗
Recent filings
4 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
4 filing
10-Q filing
NT 10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 124,360Source | 46,393Source | 78,767Source | 272,515Source | 8,735Source | 135,949Source | 110,448Source | 58,667Source | 225,901Source | 261,885Source | 103,998Source | 37,314Source |
| Property, Plant and EquipmentUSD | 15,500Source | — | 11,000Source | 17,000Source | — | 12,500Source | — | — | — | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | 18,000Source | 14,000Source | — | 15,166Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | 215,205Source | 261,885Source | 60,776Source | 25,405Source |
| Inventory, NetUSD | 44,228Source | 0Source | 36,046Source | 39,574Source | 6,000Source | 42,968Source | 40,584Source | 18,572Source | 44,706Source | 19,115Source | 15,281Source | 8,877Source |
| Assets, CurrentUSD | 108,860Source | 46,393Source | 67,767Source | 255,515Source | 8,735Source | 123,449Source | 110,448Source | 40,667Source | 211,901Source | 261,885Source | 88,557Source | 34,324Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,589,570Source | 1,851,754Source | 1,844,874Source | 1,407,813Source | 1,930,447Source | 2,272,091Source | 1,681,502Source | 1,856,550Source | 2,355,957Source | 1,725,803Source | 1,750,629Source | 1,488,815Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,093Source | 123,173Source | 3,659Source | 994Source | 123,173Source | 1,200Source | 904Source | 115,477Source | 1,200Source | 821Source | 89,576Source | 25,255Source |
| Additional Paid in CapitalUSD | 8,437,322Source | 6,861,859Source | 8,918,181Source | 8,387,834Source | 6,708,259Source | 8,700,704Source | 7,794,260Source | 6,656,867Source | 8,595,711Source | 7,704,343Source | 6,527,428Source | 6,074,763Source |
| Retained Earnings (Accumulated Deficit)USD | -9,897,858Source | -8,791,518Source | -10,682,200Source | -9,518,356Source | -8,753,869Source | -10,832,290Source | -9,360,442Source | -8,570,852Source | -10,721,204Source | -9,163,306Source | -8,264,145Source | -7,551,679Source |
| Stockholders' Equity Attributable to ParentUSD | -1,465,210Source | -1,805,361Source | -1,766,107Source | -1,135,298Source | -1,921,712Source | -2,136,142Source | -1,571,054Source | -1,797,883Source | -2,130,056Source | -1,463,918Source | -1,646,631Source | -1,451,501Source |
| Liabilities and EquityUSD | 124,360Source | 46,393Source | 78,767Source | 272,515Source | 8,735Source | 135,949Source | 110,448Source | 58,667Source | 225,901Source | 261,885Source | 103,998Source | 37,314Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,589,570Source | 1,851,754Source | 1,844,874Source | 1,407,813Source | 1,930,447Source | 2,272,091Source | 1,681,502Source | 1,856,550Source | 2,355,957Source | 1,725,803Source | 1,750,629Source | 1,488,815Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 6,939Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 162,177Source | 238,609Source | — | 152,847Source | 231,534Source | 180,837Source | 145,953Source | 215,973Source | — | 137,955Source | 1,015Source |
| Accounts Receivable | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 28,670Source | — | — | 28,670Source | — | — | 0Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | 59Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -1,738Source | 21,469Source | 25,591Source | — | 6,404Source | 4,127Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -84,839Source | -97,906Source | -516,025Source | -249,517Source | -223,773Source | -227,259Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -18,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 18,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 555,000Source | 326,211Source | 259,144Source | 169,728Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | -57,531Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 59,273Source | 43,893Source | 29,221Source | 210,582Source | 73,606Source | 39,564Source | 158,445Source | 137,470Source | 60,776Source | 25,405Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 4,728Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 0Source | 75,000Source | 0Source | 19,941Source | 28,174Source | 62,148Source |
| DepreciationUSD | — | — | — | — | 1,500Source | 1,000Source | 1,500Source | 0Source | 4,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | -201,360Source | 93,989Source | 446,730Source | 130,954Source | 174,884Source | 61,659Source | -578,645Source | -210,043Source | -307,412Source | -184,401Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | -61,659Source | 578,645Source | 210,043Source | 307,412Source | 184,401Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 101,700Source | — | 15,574Source | 0Source | — | — | 133,800Source | — | -13,200Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 250,971Source | 40,396Source | 177,745Source | 197,892Source | 181,050Source | 143,383Source | 820,508Source | 335,306Source | 101,478Source | 254,119Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -37,649Source | — | — | — | -197,136Source | — | -904,761Source | -712,466Source | -895,570Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Inventory Write-downUSD | — | — | 0Source | 60,000Source | 0Source | 0Source | — | — | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | -42Source | -148Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | -895,570Source |
| Operating ExpensesUSD | — | — | 269,540Source | 121,941Source | 201,416Source | 280,282Source | 202,331Source | 249,148Source | 1,054,670Source | 606,120Source | 239,740Source | 429,026Source |
| Other Nonoperating Income (Expense)USD | — | — | -113,813Source | 84,292Source | 347,266Source | 121,305Source | 87,132Source | 52,012Source | -515,725Source | -297,071Source | -483,545Source | -473,670Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 178,100Source | 271,587Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | 28,670Source | — | — | — |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 4,632Source | 0Source | 4,988Source | 3,219Source | 5,514Source | 0Source | 18,278Source | 12,669Source | 28,565Source | 17,176Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -265,689Source | -121,941Source | -197,176Source | -279,219Source | -198,218Source | -249,148Source | -1,042,173Source | -602,090Source | -228,921Source | — |
| Other Nonoperating Income (Expense)USD | — | — | -113,813Source | 84,292Source | 347,266Source | 121,305Source | 87,132Source | 52,012Source | -515,725Source | -297,071Source | -483,545Source | -473,670Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -379,502Source | -37,649Source | 150,090Source | -157,914Source | -111,086Source | -197,136Source | -1,557,898Source | -899,161Source | -712,466Source | -895,570Source |
| Earnings Per Share, BasicUSD per share | — | — | — | 0Source | 0.01Source | -0.02Source | — | — | — | -0.11Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | 0Source | 0Source | -0.02Source | -0.01Source | -0.02Source | -0.15Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 895,760,225Source | 14,192,536Source | 9,533,375Source | — | — | — | 8,215,426Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,239,290Source | 8,211,526Source | 281,196,262Source | 9,533,375Source | 12,008,725Source | 9,048,725Source | 10,072,563Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 0Source | 75,000Source | 0Source | 19,941Source | 28,174Source | 62,148Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | -61,659Source | 578,645Source | 210,043Source | 307,412Source | 184,401Source |
| General and Administrative ExpenseUSD | — | — | 250,971Source | 40,396Source | 177,745Source | 197,892Source | 181,050Source | 143,383Source | 820,508Source | 335,306Source | 101,478Source | 254,119Source |
| Gross ProfitUSD | — | — | 3,851Source | 0Source | 4,240Source | 1,063Source | 4,113Source | 0Source | 12,497Source | 4,030Source | 10,819Source | 7,126Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -37,649Source | — | — | — | -197,136Source | — | -904,761Source | -712,466Source | -895,570Source |
| Interest ExpenseUSD | — | — | 14,153Source | 9,697Source | — | 9,649Source | 87,757Source | 9,647Source | 70,880Source | 91,978Source | 162,891Source | 289,121Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | 15,561Source | 9,330Source | 44,466Source | 38,278Source | 43,062Source | 49,402Source |
| Operating ExpensesUSD | — | — | 269,540Source | 121,941Source | 201,416Source | 280,282Source | 202,331Source | 249,148Source | 1,054,670Source | 606,120Source | 239,740Source | 429,026Source |
| Other IncomeUSD | — | — | 0Source | — | — | 0Source | 5Source | 0Source | 0Source | 4,950Source | — | — |
| Interest Expense (non-operating) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | — | — | — | — | — |
Filing attachments
bdpt_ex991.htm · 8-K · 2025-03-18
EX-99.1 2 bdpt_ex991.htm PRESS RELEASE bdpt_ex991.htm EXHIBIT 99.1 Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone. During the trial, partici…
Read attachment ↗